Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • 4DMedical Secures U.S. Deal with Intermountain Health, Unlocking Growth Path
    4DMedical Secures U.S. Deal with Intermountain Health, Unlocking Growth Path
    • News

  • Race Oncology Doses First Patient in RC220 Trial, Advancing Tumour Program
    Race Oncology Doses First Patient in RC220 Trial, Advancing Tumour Program
    • News

  • March 2025 quarter CPI above expectations – but RBA cut still likely
    March 2025 quarter CPI above expectations – but RBA cut still likely
    • News

  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians
    Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians
    • News

  • PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease
    PYC Therapeutics Moves Toward First Treatment for Blinding Childhood Eye Disease
    • News

  • Impact Minerals Accelerates HPA Market Entry with Strategic HiPurA® Acquisition
    Impact Minerals Accelerates HPA Market Entry with Strategic HiPurA® Acquisition
    • News

  • Equity Story Acquires Baker Young to Accelerate Retail Stockbroking Expansion
    Equity Story Acquires Baker Young to Accelerate Retail Stockbroking Expansion
    • News

  • Condor Confirms 3 Billion Barrel Oil Potential in Tumbes Basin
    Condor Confirms 3 Billion Barrel Oil Potential in Tumbes Basin
    • News

  • Atomo Scales Up HIV Self-Testing Through National Vending Machine Rollout
    Atomo Scales Up HIV Self-Testing Through National Vending Machine Rollout
    • News

  • Spenda Secures $3M Term Loan to Accelerate Growth
    Spenda Secures $3M Term Loan to Accelerate Growth
    • News

RocketDNA deploys first batch of xBots for Australia and Africa, second batch scheduled

  • In News
  • April 10, 2024
  • Alinda Gupta
RocketDNA deploys first batch of xBots for Australia and Africa, second batch scheduled

Global drones-as-a-service provider RocketDNA (ASX: RKT) recently launched a new autonomous drone solution, xBot, expected to surpass its existing drone business in revenue. 

In December 2023, the Company raised approximately $1 million to accelerate the manufacturing of xBot units and increase marketing capabilities around deployment. It has successfully launched and deployed the first batch of six xBot units operational in Australia and Africa. The second batch of five xBots in production is on track, with deployments scheduled from May 2024. 

After extensive validation testing and feedback from the first xBot batch, the Company is confident in its market demand and drone manufacturing capacity for CY24. 

RocketDNA CEO Christopher Clark said, “We are very excited as a management team at the growing opportunities and pipeline and look forward to delivering on our Phase 1 ‘land-grab’ strategy. Initial sales are showing customers taking one unit first (which is always the most difficult sale) and then to plan on expanding the number of units to cover the full operating area. With our second batch of xBots® now in production, we look forward to locking in revenue contracts for these units. At that time, based on our current pricing, margins and overheads, we expect to be EBITDA positive.”

Interest in RocketDNA’s automated drone-in-a-box solution is expanding the Company’s target market beyond mining. Discussions are underway with government authorities, ports, insurance companies, asset managers, agribusinesses, and security companies. 

Moreover, RocketDNA is one of the few Civil Aviation Safety Authority (CASA) approved operators able to deploy remote autonomous drone systems at scale. This interests Tier 1 and 2 mining customers who require a full-service solution that includes after-sales support across their various operating sites.

Clark added, “With our second batch of xBots® now in production, we look forward to locking in revenue contracts for these units. At that time, based on our current pricing, margins and overheads, we expect to be EBITDA positive.”

RocketDNA has largely completed its significant upfront investment in the xBot solution and is moving through the enterprise customer trial and onboarding process. This initial process typically has many hurdles, like cyber and data security, operational health and safety, and data accuracy validations.

Last month, the Company signed its first long-term contract for its autonomous xBot solution with Keras Gold, a subsidiary of Calidus Resources. The three-year contract is worth $376k. 

At the same time, the Company has undertaken some board changes. For instance, David Morton has transitioned from being a non-executive director to the chairman role of RocketDNA. Chris Clark has transitioned from the role of Chair to focus on his role as Managing Director and CEO. This comes as RocketDNA aims to streamline the business without adding headcount. 

In CY23, RocketDNA reported revenue of $6.1 million against a loss of $1.7 million. In a bid to enter profitability, it changed its name, reimagined its board and launched xBot. While revenue growth for its existing Drones business remained flat, the Company expects xBot to see an average of 40.8% revenue growth in the coming years. 

Expectations for 2025 sales will dictate introducing additional manufacturing resources and capabilities for xBot.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx rkt
  • autonomous drone
  • Drones-as-a-service
  • RocketDNA
  • xBot
  • News

Leave a Comment

You must be logged in to post a comment.

1 Comment

  • Shraddha13
    May 1, 2025, 7:18 pm

    Thank you for sharing! To explore further
    https://www.360iresearch.com/library/intelligence/drone-as-a-service

    Reply
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.